<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00531661</url>
  </required_header>
  <id_info>
    <org_study_id>CM-06-04</org_study_id>
    <nct_id>NCT00531661</nct_id>
  </id_info>
  <brief_title>CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients</brief_title>
  <acronym>CHAMPION</acronym>
  <official_title>CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioMEMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardioMEMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, randomized, single-blind clinical trial conducted in the
      United States (US). The objective of the study is to evaluate the safety and efficacy of the
      HF Pressure Measurement System in reducing heart failure (HF) related hospitalizations in a
      subset of subjects suffering from HF.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Heart Failure Related (HFR) Hospitalizations</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom From a Device/System-related Complication (DSRC).</measure>
    <time_frame>6 months</time_frame>
    <description>A DSRC is an adverse event that is, or is possibly, related to the HF Pressure Measurement System and at least one the following:
is treated with invasive means (other than intramuscular medication or a right heart catheterization with a Swan-Ganz measurement which is used for diagnostic purposes)
results in the death of the subject
results in the explant of the device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom From Pressure Sensor Failure</measure>
    <time_frame>6 months</time_frame>
    <description>A pressure sensor failure occurs when the sensor malfunctions to the point that no readings can be obtained from it after all attempts are exhausted including troubleshooting the system to rule out any problems with the electronic components.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulmonary Artery Mean Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in pulmonary artery mean pressure was calculated using an area under the curve (AUC) methodology. All patients were instructed to take daily home readings for 180 days. By patient, a baseline average for the first 7 days of home readings was calculated. The difference between baseline and each daily reading was then determined and a corresponding daily AUC value was calculated. Finally, all daily AUC values were summed over the entire 180 day period resulting in a total AUC per patient. These data were aggregated for each randomization group and then compared. The unit of measure is mmHg x Days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Hospitalized for Heart Failure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Alive Outside of the Hospital</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Minnesota Living With Heart Failure Questionnaire (MLHFQ)</measure>
    <time_frame>6 months</time_frame>
    <description>THe MLHFQ is patient self-assessment of how heart failure affects his or her daily life. To measure the effects of symptoms, functional limitations, psychological distress on an individual's quality of life, the MLHFQ questionnaire asks each person to indicate using a 6-point, zero to five, Likert scale how much each of 21 facets prevented them from living as they desired. Total scores are provided as sums. The total score scale range is 0 - 105. A lower total score is indicative of better quality of life.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of HFR Hospitalizations</measure>
    <time_frame>Study duration: average patient follow-up of 15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Freedom From a Device/System-related Complication (DSRC)</measure>
    <time_frame>Study duration: average patient follow-up of 15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Freedom From Pressure Sensor Failure</measure>
    <time_frame>Study duration: average patient follow-up of 15 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">550</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>TREATMENT Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard of care HF management</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HF Pressure Measurement System</intervention_name>
    <description>A pressure sensor is intended to be implanted into the pulmonary artery at the time of Swan-Ganz catheterization.</description>
    <arm_group_label>TREATMENT Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of HF ≥ 3 months, with either preserved or reduced LVEF

          2. Diagnosis of NYHA Class III HF (historical assessment documented at screening visit)

          3. Subjects with reduced LVEF must be receiving a beta blocker for 3 months and an ACE-I
             or ARB for one month unless in the investigator's opinion, the subject is intolerant
             to beta blockers, ACE-I or ARB. Beta blockers and ACE-I (or ARB) doses should be
             stable for one month prior to study entry.

          4. At least 1 HF hospitalization within 12 months of Screening Visit

          5. Subjects with pulmonary artery branch diameter sized between 7mm and 15mm (implanted
             vessel)

        Exclusion Criteria:

          1. Subjects with history of recurrent (&gt; 1) pulmonary embolism or deep vein thrombosis

          2. Subjects, in the Investigator's opinion, unable to tolerate a right heart
             catheterization

          3. Subjects who have had a major cardiovascular event (e.g., myocardial infarction,
             stroke) within 2 months of Screening Visit

          4. Subjects with Cardiac Resynchronization Device (CRT) implanted ≤ 3 months prior to
             enrollment

          5. Subjects with a Glomerular Filtration Rate (GFR) &lt;25 ml/min who are non-responsive to
             diuretic therapy or who are on chronic renal dialysis

          6. Subjects likely to undergo heart transplantation within 6 months of Screening Visit

          7. Subjects with congenital heart disease or mechanical right heart valve(s)

          8. Subjects with known coagulation disorders

          9. Subjects with a hypersensitivity or allergy to aspirin, and/or clopidogrel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip Adamson, MD, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William T Abraham, MD, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CardioMEMS Investigational Sites</name>
      <address>
        <city>Nationwide</city>
        <state>Georgia</state>
        <zip>30313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2007</study_first_submitted>
  <study_first_submitted_qc>September 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2007</study_first_posted>
  <results_first_submitted>November 16, 2012</results_first_submitted>
  <results_first_submitted_qc>February 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2013</results_first_posted>
  <last_update_submitted>January 16, 2015</last_update_submitted>
  <last_update_submitted_qc>January 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>TREATMENT group: standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>CONTROL group: standard of care HF management</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>6 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="280"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="254"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Study Duration: 15 Months Avg. Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="254"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
                <participants group_id="P2" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>TREATMENT group: standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>CONTROL group: standard of care HF management</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="270"/>
            <count group_id="B2" value="280"/>
            <count group_id="B3" value="550"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="13.0"/>
                    <measurement group_id="B2" value="61.8" spread="12.7"/>
                    <measurement group_id="B3" value="61.6" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                    <measurement group_id="B2" value="280"/>
                    <measurement group_id="B3" value="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Heart Failure Related (HFR) Hospitalizations</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>TREATMENT group: standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CONTROL group: standard of care HF management</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Heart Failure Related (HFR) Hospitalizations</title>
          <units>HFR hospitalizations/patient/6 months</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32"/>
                    <measurement group_id="O2" value="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Negative Binomial Regression</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Freedom From a Device/System-related Complication (DSRC).</title>
        <description>A DSRC is an adverse event that is, or is possibly, related to the HF Pressure Measurement System and at least one the following:
is treated with invasive means (other than intramuscular medication or a right heart catheterization with a Swan-Ganz measurement which is used for diagnostic purposes)
results in the death of the subject
results in the explant of the device</description>
        <time_frame>6 months</time_frame>
        <population>This Safety Endpoint was prespecified as an aggregate analysis of all patients implanted with the device as well as patients where an implant was attempted. Results are not presented as an inter-arm comparison but rather against an objective performance criteria (OPC). This population includes 550 implanted patients + 25 patient attempts.</population>
        <group_list>
          <group group_id="O1">
            <title>Entire Study Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>Freedom From a Device/System-related Complication (DSRC).</title>
          <description>A DSRC is an adverse event that is, or is possibly, related to the HF Pressure Measurement System and at least one the following:
is treated with invasive means (other than intramuscular medication or a right heart catheterization with a Swan-Ganz measurement which is used for diagnostic purposes)
results in the death of the subject
results in the explant of the device</description>
          <population>This Safety Endpoint was prespecified as an aggregate analysis of all patients implanted with the device as well as patients where an implant was attempted. Results are not presented as an inter-arm comparison but rather against an objective performance criteria (OPC). This population includes 550 implanted patients + 25 patient attempts.</population>
          <units>cases</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="550"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implantation Cases</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="575"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="567" lower_limit="97.3%" upper_limit="99.4%"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis of DSRC was based on the following pre-specified objective performance criteria: the lower limit of the two-sided 95.2% confidence interval on the freedom from DSRC rate for all implantation cases was at least 80%. The statistical hypotheses were:
Null: (Freedom from device / system-related complications) ≤ 80%
Alternative: (Freedom from device / system-related complications) &gt; 80%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>exact test of binomial proportions</method>
            <method_desc>P-value from exact test of binomial proportions compared proportion of all implantation cases free from DSRC to OPC of 0.80.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Freedom From Pressure Sensor Failure</title>
        <description>A pressure sensor failure occurs when the sensor malfunctions to the point that no readings can be obtained from it after all attempts are exhausted including troubleshooting the system to rule out any problems with the electronic components.</description>
        <time_frame>6 months</time_frame>
        <population>This Safety Endpoint was prespecified as an aggregate analysis of all patients implanted with the device. Results are not presented as an inter-arm comparison but rather against an objective performance criteria (OPC).</population>
        <group_list>
          <group group_id="O1">
            <title>Entire Randomized Study Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Pressure Sensor Failure</title>
          <description>A pressure sensor failure occurs when the sensor malfunctions to the point that no readings can be obtained from it after all attempts are exhausted including troubleshooting the system to rule out any problems with the electronic components.</description>
          <population>This Safety Endpoint was prespecified as an aggregate analysis of all patients implanted with the device. Results are not presented as an inter-arm comparison but rather against an objective performance criteria (OPC).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis of sensor failures was based on the following pre-specified objective performance criteria: the lower limit of the two-sided 95.2% confidence interval on the freedom from pressure sensor failure rate for all patients implanted was at least 90%. The statistical hypotheses were:
Null: (Freedom from device / system-related complications) ≤ 90%
Alternative: (Freedom from device / system-related complications) &gt; 90%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>exact test of binomial proportions</method>
            <method_desc>P-value from exact test of binomial proportions compared proportion of all implanted patients free from pressure sensor failure to OPC of 0.90.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulmonary Artery Mean Pressure</title>
        <description>Change from baseline in pulmonary artery mean pressure was calculated using an area under the curve (AUC) methodology. All patients were instructed to take daily home readings for 180 days. By patient, a baseline average for the first 7 days of home readings was calculated. The difference between baseline and each daily reading was then determined and a corresponding daily AUC value was calculated. Finally, all daily AUC values were summed over the entire 180 day period resulting in a total AUC per patient. These data were aggregated for each randomization group and then compared. The unit of measure is mmHg x Days.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>TREATMENT group: standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CONTROL group: standard of care HF management</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulmonary Artery Mean Pressure</title>
          <description>Change from baseline in pulmonary artery mean pressure was calculated using an area under the curve (AUC) methodology. All patients were instructed to take daily home readings for 180 days. By patient, a baseline average for the first 7 days of home readings was calculated. The difference between baseline and each daily reading was then determined and a corresponding daily AUC value was calculated. Finally, all daily AUC values were summed over the entire 180 day period resulting in a total AUC per patient. These data were aggregated for each randomization group and then compared. The unit of measure is mmHg x Days.</description>
          <units>mmHg * days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-155.7" spread="1088.0"/>
                    <measurement group_id="O2" value="33.1" spread="951.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0077</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Hospitalized for Heart Failure</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>TREATMENT group: standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CONTROL group: standard of care HF management</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Hospitalized for Heart Failure</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0292</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Alive Outside of the Hospital</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>TREATMENT group: standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CONTROL group: standard of care HF management</description>
          </group>
        </group_list>
        <measure>
          <title>Days Alive Outside of the Hospital</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.4" spread="31.1"/>
                    <measurement group_id="O2" value="172.1" spread="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0280</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Minnesota Living With Heart Failure Questionnaire (MLHFQ)</title>
        <description>THe MLHFQ is patient self-assessment of how heart failure affects his or her daily life. To measure the effects of symptoms, functional limitations, psychological distress on an individual’s quality of life, the MLHFQ questionnaire asks each person to indicate using a 6-point, zero to five, Likert scale how much each of 21 facets prevented them from living as they desired. Total scores are provided as sums. The total score scale range is 0 - 105. A lower total score is indicative of better quality of life.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>TREATMENT group: standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CONTROL group: standard of care HF management</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Minnesota Living With Heart Failure Questionnaire (MLHFQ)</title>
          <description>THe MLHFQ is patient self-assessment of how heart failure affects his or her daily life. To measure the effects of symptoms, functional limitations, psychological distress on an individual’s quality of life, the MLHFQ questionnaire asks each person to indicate using a 6-point, zero to five, Likert scale how much each of 21 facets prevented them from living as they desired. Total scores are provided as sums. The total score scale range is 0 - 105. A lower total score is indicative of better quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" spread="26.4"/>
                    <measurement group_id="O2" value="50.6" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0236</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Rate of HFR Hospitalizations</title>
        <time_frame>Study duration: average patient follow-up of 15 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>TREATMENT group: standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CONTROL group: standard of care HF management</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of HFR Hospitalizations</title>
          <units>HFR hospitalizations/patient-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46"/>
                    <measurement group_id="O2" value="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Negative Binomial Regression</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Freedom From a Device/System-related Complication (DSRC)</title>
        <time_frame>Study duration: average patient follow-up of 15 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Duration Study Cohort</title>
            <description>Safety endpoint evaluated for all patients having follow-up after the 6-month primary period.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From a Device/System-related Complication (DSRC)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="498"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis of DSRC was based on the following pre-specified objective performance criteria: the lower limit of the two-sided 95.2% confidence interval on the freedom from DSRC rate for all implanted patients was at least 80%. The statistical hypotheses were:
Null: (Freedom from device / system-related complications) ≤ 80%
Alternative: (Freedom from device / system-related complications) &gt; 80%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>exact test of binomial proportions</method>
            <method_desc>P-value from exact test of binomial proportions compared proportion of all implanted patients free from DSRC to OPC of 0.80.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Freedom From Pressure Sensor Failure</title>
        <time_frame>Study duration: average patient follow-up of 15 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Duration Study Cohort</title>
            <description>Safety endpoint evaluated for all patients having follow-up after the 6-month primary period.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Pressure Sensor Failure</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="498"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis of sensor failures was based on the following pre-specified objective performance criteria: the lower limit of the two-sided 95.2% confidence interval on the freedom from pressure sensor failure rate for all implanted patients was at least 90%. The statistical hypotheses were:
Null: (Freedom from device / system-related complications) ≤ 90%
Alternative: (Freedom from device / system-related complications) &gt; 90%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>exact test of binomial proportions</method>
            <method_desc>P-value from exact test of binomial proportions compared proportion of all implanted patients free from pressure sensor failure to OPC of 0.90.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>TREATMENT group: standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>CONTROL group: standard of care HF management</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="155" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" events="144" subjects_affected="76" subjects_at_risk="270"/>
                <counts group_id="E2" events="187" subjects_affected="101" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="270"/>
                <counts group_id="E2" events="19" subjects_affected="12" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>general disorders</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="270"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infections</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="270"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>metabolism and nutrition</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="270"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>nervous system</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="270"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal and urinary</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="270"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="270"/>
                <counts group_id="E2" events="31" subjects_affected="25" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>surgical</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="270"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>vascular</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="270"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="174" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>blood and lymphatic system</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="270"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac</sub_title>
                <counts group_id="E1" events="73" subjects_affected="47" subjects_at_risk="270"/>
                <counts group_id="E2" events="58" subjects_affected="38" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal</sub_title>
                <counts group_id="E1" events="61" subjects_affected="42" subjects_at_risk="270"/>
                <counts group_id="E2" events="49" subjects_affected="34" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>general disorders</sub_title>
                <counts group_id="E1" events="44" subjects_affected="35" subjects_at_risk="270"/>
                <counts group_id="E2" events="30" subjects_affected="24" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infections</sub_title>
                <counts group_id="E1" events="50" subjects_affected="38" subjects_at_risk="270"/>
                <counts group_id="E2" events="56" subjects_affected="46" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>injury</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="270"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>investigations</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="270"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>metabolism and nutrition</sub_title>
                <counts group_id="E1" events="57" subjects_affected="43" subjects_at_risk="270"/>
                <counts group_id="E2" events="33" subjects_affected="29" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal</sub_title>
                <counts group_id="E1" events="34" subjects_affected="29" subjects_at_risk="270"/>
                <counts group_id="E2" events="33" subjects_affected="27" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>nervous system</sub_title>
                <counts group_id="E1" events="47" subjects_affected="38" subjects_at_risk="270"/>
                <counts group_id="E2" events="32" subjects_affected="24" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>psychiatric</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="270"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal and urinary</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="270"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>respiratory</sub_title>
                <counts group_id="E1" events="51" subjects_affected="42" subjects_at_risk="270"/>
                <counts group_id="E2" events="62" subjects_affected="44" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin and subcutaneous tissue</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="270"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>vascular</sub_title>
                <counts group_id="E1" events="30" subjects_affected="24" subjects_at_risk="270"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="280"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jordan Bauman</name_or_title>
      <organization>CardioMEMS, Inc.</organization>
      <phone>4043458235</phone>
      <email>jbauman@cardiomems.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

